0001193125-21-225439.txt : 20210826 0001193125-21-225439.hdr.sgml : 20210826 20210727134427 ACCESSION NUMBER: 0001193125-21-225439 CONFORMED SUBMISSION TYPE: CORRESP PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20210727 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Omega Therapeutics, Inc. CENTRAL INDEX KEY: 0001850838 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CORRESP BUSINESS ADDRESS: STREET 1: 20 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: (617) 949-4360 MAIL ADDRESS: STREET 1: 20 ACORN PARK DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02140 CORRESP 1 filename1.htm CORRESP

July 27, 2021

VIA EDGAR

U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

 

Re:

Omega Therapeutics, Inc.

Registration Statement on Form S-1

Registration No. 333-257794

Acceleration Request

Requested Date: July 29, 2021

Requested Time: 4:00 PM, Eastern Daylight Time

Ladies and Gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Goldman Sachs & Co. LLC, Jefferies LLC and Piper Sandler & Co., as representatives of the several underwriters, hereby join Omega Therapeutics, Inc. in requesting that the Securities and Exchange Commission (the “Commission”) take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-257794) (the “Registration Statement”) to become effective on July 29, 2021, at 4:00 PM, Eastern Daylight Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

[Signature Page Follows]


Very truly yours,
Goldman Sachs & Co. LLC
By:  

/s/ Elizabeth Wood

Name:   Elizabeth Wood
Title:   Managing Director

 

Jefferies LLC
By:  

/s/ Dustin Tyner

Name:   Dustin Tyner
Title:   Managing Director

 

Piper Sandler & Co.
By:  

/s/ Neil Riley

Name:   Neil Riley
Title:   Managing Director

 

cc:

Mahesh Karande, Omega Therapeutics, Inc.

Robert E. Puopolo, Goodwin Procter LLP

Seo Salimi, Goodwin Procter LLP

Peter N. Handrinos, Latham & Watkins LLP

Wesley C. Holmes, Latham & Watkins LLP

 

[Signature Page to Acceleration Request]